Tests a stomach muscle cut procedure for weight loss in adults with obesity
Studies a stomach procedure, alone, for weight loss in adults with obesity.
Key facts
- Who runs it
- Christopher C. Thompson, MD, MSc
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 22 Sept 2023
- Expected to end
- Dec 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- PSAM Treatment Patients
- Record updated
- 2 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a BMI above 35 kg/m2 who can have an endoscopic or surgical weight loss procedure. It tests a stomach muscle cut called PSAM for weight loss.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Body mass index (BMI) greater than 35 kg/m2.
- Earlier treatment
- No opioid treatment in the 12 months before joining. No earlier pyloromyotomy or pyloroplasty. No earlier stomach or bowel surgery.
Main reasons for not taking part
- Untreated H. pylori infection or gastroparesis
- Active smoking
- Pregnancy, puerperium or lactation
- Inflammatory, malignant or premalignant disease of the stomach or gut
- Severe heart or lung disease, or a history of coronary artery disease
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- subjects must be 18-70 years of age
- eligible for endoscopic and surgical weight loss procedures
- body mass index (BMI) greater than 35 kg/m2
- Individuals must be in excellent mental health
- able to understand and sign informed consent
- available to return for all routine follow-up study visits
Who cannot take part
- an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment
- previous pyloromyotomy or pyloroplasty
- use of any medication that may interfere with weight loss
- use of any medication that may interfere with gastric emptying
- untreated H. pylori infection
- any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)
- malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)
- severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)
- history of gastrointestinal surgery
- any serious health condition unrelated to their weight that would increase the risk of endoscopy
- a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)
- any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study
- gastroparesis
- active smoking
- gastrointestinal obstruction
- severe coagulopathy
- esophageal or gastric varices and/or portal hypertensive gastropathy
- pregnancy or puerperium
- lactation
- chronic abdominal pain
- active psychological issues preventing participation in a lifestyle modification program
- an inability to provide informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Michele B. Ryan, MSTaking people
About the trial
What the trial wants to find out
Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.
The 3 groups in the trial
- PSAM Treatment Patients with no prior endoscopic bariatric therapies
Subjects with no prior endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Treatment: PSAM Treatment Patients
- PSAM Treatment Patients with prior primary endoscopic bariatric therapies
Subjects with prior primary endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Treatment: PSAM Treatment Patients
- PSAM Treatment Patients with prior revision endoscopic bariatric therapies
Subjects with prior revision endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Treatment: PSAM Treatment Patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study
- Plain-language title
- Tests a stomach muscle cut procedure for weight loss in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05711758, who can take part
- Record updated
- 2 March 2026